Please check your internet connection and try again.
# Clobazam (Oral Formulation)
## Overview
Clobazam is a 1,5-benzodiazepine with anticonvulsant properties. It is primarily used as adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS).
## Primary Indications
* Adjunctive treatment of seizures in patients with Lennox-Gastaut syndrome (LGS).
## Adult Dosing
* **Initiation:** 5 mg twice daily.
* **Titration:** Increase dose by 5 mg to 10 mg every week as tolerated, up to a maximum of 20 mg twice daily.
* **Maintenance:** Doses can range from 10 mg to 20 mg twice daily.
## Pediatric Dosing
* **LGS (2 years and older):**
* **Initiation:** 0.5 mg/kg/day divided into two doses.
* **Titration:** Increase dose by 0.5 mg/kg/day every week as tolerated, divided into two doses, up to a maximum of 1 mg/kg/day divided into two doses (maximum daily dose 20 mg).
* **Dosing for children younger than 2 years is not established.**
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. No specific dose adjustments are provided, but starting at the lower end of the dose range and titrating slowly is recommended due to potential for increased drug exposure.
* **Renal Impairment:** Use with caution. No specific dose adjustments are provided.
## Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
## Adverse Effects
* **Common:** Somnolence, decreased appetite, constipation, drooling, fatigue, aggression, irritability, upper respiratory tract infection, vomiting, gait disturbance, pyrexia.
* **Serious:** Severe skin reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis), suicidal behavior and ideation, respiratory depression, dependence and withdrawal symptoms, paradoxical reactions (e.g., hyperactivity, hallucinations).
## Key Drug Interactions
* **CNS Depressants:** Additive CNS depressant effects with alcohol, opioids, other benzodiazepines, sedating antihistamines, and antipsychotics.
* **CYP3A4 Substrates/Inhibitors:** Clobazam is metabolized by CYP2C19 and CYP3A4. Concomitant use with strong CYP3A4 inhibitors may increase clobazam levels. Concomitant use with strong CYP3A4 inducers may decrease clobazam levels.
* **Valproic Acid:** Concomitant use may lead to increased valproic acid levels. Monitor valproic acid levels and consider dose adjustment.
## Monitoring
* Monitor for efficacy (seizure frequency).
* Monitor for adverse effects, particularly somnolence, fatigue, and behavioral changes.
* Monitor for signs of dependence and withdrawal upon discontinuation.
* Monitor for suicidal behavior and ideation.
* Monitor for severe skin reactions.
## Clinical Pearls
* Clobazam should be withdrawn gradually to avoid withdrawal symptoms.
* Caution patients about operating heavy machinery or driving until they know how clobazam affects them.
* Consider the potential for increased sedation when co-administered with other CNS depressants.
* The active metabolite, N-desmethylclobazam (norclobazam), has a long half-life and contributes significantly to the drug's effects.
***
**Disclaimer:** This information is intended for healthcare professionals. Always consult the current prescribing information and relevant guidelines for complete details. Dosing and management may vary based on individual patient factors and local protocols.
